Use of botulinum toxin type A in children with cerebral palsy

Physical Therapy

Volumn 86, Issue 4, 2006, Pages 573-584

  Nolan, Karen W ^a   Cole, Lynn L ^b   Liptak, Gregory S ^b  

^a ITHACA COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cerebral palsy; Drugs; Spasticity

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

CEREBRAL PALSY; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DEFORMITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSTONIA; FALLING; FATIGUE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GAIT; HUMAN; MOTOR PERFORMANCE; MUSCLE WEAKNESS; NEUROMUSCULAR SYNAPSE; PAIN; PHYSIOTHERAPIST; PHYSIOTHERAPY; RANGE OF MOTION; RASH; RATING SCALE; REVIEW; SPASTICITY; URINE INCONTINENCE;

EID: 33645580448     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.1093/ptj/86.4.573     Document Type: Review

References (47)

1. Koman LA, Smith BP, Shut JS. Cerebral palsy. Lancet. 2004;363:1619-1631.
2. Lance JW. Symposium synopsis. In: Feldman FG, Young RR, Koella WP, eds. Spasticity: Disorder of Motor Control. Chicago, Ill: Year Book Medical; 1980:485-494.
3. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equines: a randomized prospective trial. J Pediatr Orthop. 1998;18:304-311.
4. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol. 2004;46:491-499.
5. Kessler KR, Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicol. 1997;18:761.
6. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6-12.
7. Transfer of therapeutic products to the Center for Drug Evaluation and Research. US Food and Drug Administration, Center for Biologics Evaluation and Research. Available at: www.fda.gov/cber/transfer/ transfprods.htm. Accessed August 30, 2005.
8. Savino PJ, Sergott RC, Bosley TM, et al. Hemifacial spasm treated with botulinum A toxin injection. Arch Opthalmol. 1985;103:1305-1306.
9. Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia: a preliminary report. Arch Otolaryngol Head Neck Surg. 1987;113:603-605.
10. Snow BJ, Tsui JKC, Bhatt M, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512-515.
11. Koman LA, Mooney JF, Smith B, et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993;13:489-495.
12. Koman LA, Mooney JF, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000;20:108-115.
13. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994;36:386-396.
14. Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol. 2001;16:37-46.
15. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs. 2000;59:487-495.
16. DePavia A, Meiunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999;96:3200-3205.
17. Priess RA, Condie DN, Rowley DI, Graham HK. The effects of botulinum toxin (Btx-A) on spasticity of the lower limb and on gait in cerebral palsy. J Bone Joint Surg Br. 2003;85:943-948.
18. Bakheit AMO, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol. 2001;43:234-238; erratum 2001;43:357.
19. Bakheit AMO, Ward CD, McLellan DL. Generalised botulism-like syndrome after the intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198.
20. Bhatia JP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67:90-93.
21. Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11:67-79.
22. Bell KR, Williams E. Use of botulinum toxin type A and type B for spasticity in upper and lower limbs. Phys Med Rehabil Clin N Am. 2003;14:821-835.
23. Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics. 1999;30:120-124.
24. Heinen F, Wissell J, Philipsen A, et al. Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics. 1997;28:307-313.
25. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol. 1998;18:124-130.
26. Mall V, Keinen F, Kirschner J, et al. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol. 2000;15:214-217.
27. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, et al. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol. 1994;10:284-288.
28. Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol. 1994;36:379-385.
29. Thompson NS, Baker RJ, Cosgrove AP, et al. Musculoskeletal modeling in determining the effect of botulinum toxin on the hamstrings of patients, with crouch gait. Dev Med Child Neurol. 1998;40:622-625.
30. Eames NW, Baker RJ, Hill N, et al. The effect of botulinum toxin A on gastrocnemuis length: magnitude and duration of response. Dev Med Child Neurol. 1999;41:226-232.
31. Zelnik N, Giladi N, Goikhman I, et al. The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy-a pilot study. Isr J Med Sci. 1997;33:129-133.
32. Denislic M, Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics. 1995;26:249-252.
33. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in hemiplegic cerebral palsy. J Pediatr. 2000;137:331-337.
34. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-223.
35. Sutherland DH, Kaufman KR, Wyatt MP, et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10:1-9.
36. Boyd RN, Pliatsios V, Starr R, et al. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol. 2000;42:32-41.
37. Wallen MA, O'Flaherty SJ, Waugh MCA. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil. 2004;85:192-200.
38. Wong AM, Chen CL, Chen CP, et al. Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy. Am J Phys Med Rehabil. 2004;83:284-291.
39. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206-207.
40. Fosang AL, Galea MP, McCoy AT, et al. Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol. 2003;45:664-670.
41. Heinen F, Linder M, Mall V, et al. Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: the parents view of functional outcome. Eur J Neurol. 1999;6(suppl 4):S47-S50.
42. Russell DJ, Rosenbaum PL, Avery LM, Lane M. Gross Motor Function Measure (GMFM-66 and GMFM-88) User's Manual. London, United Kingdom: Mac Keith Press; 2002.
43. Leach J. Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve Suppl. 1997;6:S194-S207.
44. Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. March 2004:58-65.
45. Damiano DL, Kelly LE, Vaughan C. Effects of quadriceps femoris muscle strengthening on crouch gait in children with spastic diplegia. Phys Ther. 1995;75:658-671.
46. Damiano DL, Dodd K, Taylor NF. Should we be testing and training muscle strength in cerebral palsy? Dev Med Child Neural 2002;44:68-72.
47. Ketelaar M, Vermeer A, Hart H, et al. Effects of a functional therapy program on motor abilities of children with cerebral palsy. Phys Ther. 2001;81:1534-1545.